Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | PNMT | P11086 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200187 | 0.87 | GABRA1 (0.55) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 | |
| SCHEMBL22801396 | 0.85 | CYP1A2 (0.68) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 | |
| SCHEMBL11501928 | 0.83 | CYP1A2 (0.65) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 | |
| SCHEMBL10980261 | 0.81 | CYP1A2 (0.63) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 | |
| Methylamine SCHEMBL6500291 | 0.81 | PNMT (0.69) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 | |
| SCHEMBL8207165 | 0.81 | PNMT (1.00) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 | |
| SCHEMBL8207792 | 0.81 | PNMT (1.00) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 | |
| SCHEMBL8428077 | 0.81 | CYP1A2 (0.63) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 | |
| SCHEMBL15302407 | 0.81 | CYP1A2 (0.63) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 | |
| SCHEMBL158333 | 0.81 | PNMT (1.00) | CYP1A2CYP3A4PNMTCYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5869737-A | REACTING A MALONIC ACID DERIVATIVE AND A 1,2-DICHLORO COMPOUND WITH AN ALCOHOLATE; CYCLIZATION; SOLVENT EXTRACTION; DISTILLATION | HUELS AKTIENGESELLSCHAFT (DE) | 1999-02-09 | — | — | US | claimed |
| WO-2024092083-A1 | SMALL MOLECULAR WEIGHT CHEMICAL COMPOUND TO ANTAGONIZE EPH-EPHRIN TETRAMERIZATION AND INHIBIT BIDIRECTIONAL SIGNALING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-01-02 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2007002172-A2 | HIV-1 PROTEASE INHIBITORS | UNIVERSITY OF MASSACHUSETTS (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5869737-A | REACTING A MALONIC ACID DERIVATIVE AND A 1,2-DICHLORO COMPOUND WITH AN ALCOHOLATE; CYCLIZATION; SOLVENT EXTRACTION; DISTILLATION | HUELS AKTIENGESELLSCHAFT (DE) | 1999-02-09 | — | — | US | disclosed |
| EP-0442115-B1 | Process for nucleus-chlorination of aromatic hydrocarbons | BAYER AG (DE) | 1993-11-24 | — | — | EP | disclosed |
| US-5105036-A | Friedel-Crafts catalyst and oxy-substituted cyclic amidines as cocatylsts; preferential formation of p-isomer | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-14 | — | — | US | disclosed |
| EP-0442115-A1 | Process for nucleus-chlorination of aromatic hydrocarbons | BAYER AG (DE) | 1991-08-21 | — | — | EP | disclosed |
| US-5030777-A | Synthesis of 3,5-dichloroalkylbenzene and recovery of 1,3-dichlorobenzene | STANDARD CHLORINE OF DELAWARE, INC. (US) | 1991-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067636-A1 | PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN1 | CYP1A2 3366/4885CYP3A4 3646/4885PNMT 4271/4885 |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | ERG28, UGCG, DPM1 | CYP1A2 3604/4885CYP3A4 3930/4885PNMT 1993/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | CYP1A2 2970/4885CYP3A4 4070/4885PNMT 3009/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | CYP1A2 3478/4885CYP3A4 3711/4885PNMT 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.